Vista Pharmaceuticals (524711) Q1 24/25 earnings summary

Executive summary

• Board approved unaudited financial results for the quarter ended June 30, 2024, and related limited review report.

• Reappointments of two directors and AGM notice for September 30, 2024, were approved.

• Appointment of scrutinizer for AGM voting process confirmed.

Financial highlights

• Revenue from operations for Q1 FY25 was ₹179.50 lakhs, down from ₹198.10 lakhs in Q1 FY24.

• Total income for the quarter was ₹186.61 lakhs, compared to ₹211.31 lakhs in the same quarter last year.

• Loss before tax for Q1 FY25 was ₹117.13 lakhs, compared to a loss of ₹128.91 lakhs in Q1 FY24.

• Net loss for the quarter was ₹85.70 lakhs, compared to a net loss of ₹95.46 lakhs in Q1 FY24.

• Basic and diluted EPS for the quarter stood at -0.15.

Key financial ratios and metrics

• Gross margin and EBITDA not explicitly disclosed; focus on net loss and EPS.

• Paid-up equity share capital as of June 30, 2024, was ₹1231.04 lakhs.